The viral vector manufacturing market
is expected to reach USD 815.8 million by 2023 from an estimated USD
327.8 million in 2018, at a CAGR of 20.0%. The key factors driving the
growth of this market include rising prevalence of cancer and genetic
disorders, funding for the development of novel therapies, effectiveness
of viral vectors in gene therapy delivery, and ongoing research into
viral vector-based gene and cell therapies.
“North America is expected to dominate the viral vector manufacturing market in 2018”
In
2018, North America is estimated to account for the largest share of
the viral vector manufacturing market. Factors such as a large number of
regenerative medicine companies (including gene and cell therapy
companies), increasing research activities, rising prevalence of target
diseases, and availability of funds are supporting the growth of the
viral vector manufacturing market in North America.
The
major players in the global viral vector manufacturing market are Lonza
(Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult
(UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth
Biotechnologies (US), Kaneka Eurogentec (Japan), and Spark Therapeutics
(US).
More info:
Comments
Post a Comment